Search Clinical Trials
Before medications are approved by the U.S. Food and Drug Administration (FDA) or before certain therapy methods are widely accepted as effective, they are tested on people who volunteer to participate in a clinical trial.
Organizations across the country are looking for people like you to take part in their research studies. The list of studies below have been selected from ClinicalTrials.gov based on their inclusion of one or more of the following terms: anxiety disorders, depression, OCD, PTSD, and bipolar disorder.
The Anxiety and Depression Association of America (ADAA) is supportive of research that is conducted through clinical trials. Participating in research can potentially help change the mental health outcomes for you and others who suffer anxiety, depression, and related disorders. You may learn about new interventions/treatments that are being considered.
Read this ADAA blog about things to know and questions to ask before committing to a clinical trial.
This website page is brought to you in partnership with ResearchMatch.
Sponsor Condition of Interest |
---|
Depressed Mood Improvement Through Nicotine Dosing 3
Vanderbilt University Medical Center
Depressive Disorder
Deficits in cognitive control are core features of late-life depression (LLD),
contributing both to emotion dysregulation and problems with inhibiting irrelevant
information, conflict detection, and working memory. Clinically characterized as
executive dysfunction, these deficits are associated wit1 expand
Deficits in cognitive control are core features of late-life depression (LLD), contributing both to emotion dysregulation and problems with inhibiting irrelevant information, conflict detection, and working memory. Clinically characterized as executive dysfunction, these deficits are associated with poor response to antidepressants and higher levels of disability. Improvement of cognitive control network (CCN) dysfunction may benefit both mood and cognitive performance, however no current pharmacotherapy improves Cognitive Control Network deficits in LLD. The study examines the hypothesis that nicotine acetylcholine receptor agonists enhance Cognitive Control Network function. This effect may resultantly improve mood and cognitive performance in LLD. Small, open-label studies of transdermal nicotine (TDN) patches have supported potential clinical benefit and provided support that transdermal nicotine administration engages the Cognitive Control Network. This blinded study will expand past open-label trials supporting potential benefit in LLD. It will examine TDN's effect on depression severity and cognitive control functions measured by neuropsychological testing. The study will evaluate 60 eligible and enrolled participants over a 3-year period. Type: Interventional Start Date: Apr 2023 |
Early Intervention Following Sexual Assault
Medical University of South Carolina
Ptsd
Alcohol Use Disorder
Sexual Assault and Rape
This study is for women who have experienced a sexual assault in the past six weeks and
use alcohol. The research involves completing a five week behavioral treatment for stress
and alcohol use. Participants will complete surveys during visits. Participants may also
be asked to complete brief daily1 expand
This study is for women who have experienced a sexual assault in the past six weeks and use alcohol. The research involves completing a five week behavioral treatment for stress and alcohol use. Participants will complete surveys during visits. Participants may also be asked to complete brief daily assessments on their smart phones. Type: Interventional Start Date: Dec 2020 |
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neurops1
Massachusetts General Hospital
Traumatic Brain Injury
Major Depressive Disorder
Bipolar Disorder
Schizophrenia
Attention Deficit Hyperactivity Disorder
In the current study, the investigators aim to understand the role of transcranial direct
current stimulation (tDCS) in improving executive function across neuropsychiatric
populations known to have deficits in this cognitive domain. expand
In the current study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain. Type: Interventional Start Date: Sep 2014 |
MRI Markers of Feedback Timing During Learning in Individuals with TBI with and Without Clinical De1
Kessler Foundation
Traumatic Brain Injury
Major Depressive Disorder
The goal of this proposal is to examine the influence of feedback timing on learning and
brain function in individuals with moderate-to-severe traumatic brain injury (TBI), with
and without depression. expand
The goal of this proposal is to examine the influence of feedback timing on learning and brain function in individuals with moderate-to-severe traumatic brain injury (TBI), with and without depression. Type: Interventional Start Date: Sep 2021 |
Respiratory Training vs Interoceptive Exposure in the Treatment of Transdiagnostic Pathological Anx1
University of Texas at Austin
Anxiety Disorders
Trauma
Generalized Anxiety Disorder
Panic Disorder
Agoraphobia
Purpose of the Research: The primary aim of the proposed study is to conduct a randomized
parallel-group 3-arm clinical trial comparing two mechanistically distinct interventions
for pathological anxiety - (1) Interoceptive Exposure (IE) utilizing graduated exposure
to somatic cues (respiratory, ca1 expand
Purpose of the Research: The primary aim of the proposed study is to conduct a randomized parallel-group 3-arm clinical trial comparing two mechanistically distinct interventions for pathological anxiety - (1) Interoceptive Exposure (IE) utilizing graduated exposure to somatic cues (respiratory, cardiac, vestibular) with the primary aim of reducing fear responding to the presence of interoceptive perturbations; (2) Capnometry-Guided Respiratory Intervention (CGRI) aimed at raising end-tidal CO2 levels thereby lowering hyperventilation-induced respiratory alkalosis and its associated fear-eliciting somatic reactions; and (3) Psycho-education about anxiety and its effects (PsyEd), which will serve as a credible control comparator. Type: Interventional Start Date: Aug 2022 |
Characterization and Treatment of Adolescent Depression
National Institute of Mental Health (NIMH)
Depression
This research study seeks to find causes and treatments of depression in teenagers. The
study goals are to increase our knowledge of treatments for depression and understand how
the brain changes when teenagers have depression. The study will also compare teenagers
with depression to those without1 expand
This research study seeks to find causes and treatments of depression in teenagers. The study goals are to increase our knowledge of treatments for depression and understand how the brain changes when teenagers have depression. The study will also compare teenagers with depression to those without mental health diagnoses. This outpatient study is recruiting participants ages 11-17 who are depressed. They must have a pediatrician or other medical provider, be medically healthy, and able to perform research tasks. They may not currently be hospitalized, psychotic or actively suicidal. Teenagers with depression are eligible even if they are taking medication. The study begins with an evaluation that includes clinical assessment, interviews, and questionnaires. - Visits may include paper-and-pencil and computer tests of mood, memory, and thinking; specialized computer games; and structural and brain imaging. If eligible, study participants may return several times a year for up to two years. This part of the study does not involve treatment. - Participants may be eligible for outpatient treatment for up to 25 weeks. This includes evidenced-based "talk" therapy. Participants may choose either Interpersonal Psychotherapy for Adolescents (IPT-A) or Cognitive Behavioral Therapy (CBT). If indicated, participants may opt to receive standard medication treatments along with psychotherapy. Research includes computer tasks and brain imaging. All clinical evaluations, research tasks and visits are free of cost. Participants are compensated for research activities. Parents and teenager must agree to the teenager s participation in research. The study is conducted at the NIH in Bethesda, Maryland and enrolls participants from the Washington DC Metro region within 50 miles of NIH. Transportation expenses are reimbursed by NIMH. Type: Observational Start Date: Dec 2017 |
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar1
Bristol-Myers Squibb
Bipolar-I Disorder With Mania or Mania With Mixed Features
The purpose of this study is to evaluate the efficacy and safety of KarXT for the
treatment of manic episodes in Bipolar-I Disorder expand
The purpose of this study is to evaluate the efficacy and safety of KarXT for the treatment of manic episodes in Bipolar-I Disorder Type: Interventional Start Date: Jun 2025 |
Brain Activity Changes After Cognitive Behavioral Therapy for Anxiety in Autistic Youth From High-N1
Montclair State University
Autism Spectrum Disorder
Anxiety
The goal of this clinical trial is to investigate neural constructs related to anxiety
symptoms in response to Facing Your Fears (FYF) treatment in autistic participants with
co-occurring anxiety.
Researchers will compare participants receiving immediate FYF intervention to those in
the waitlist c1 expand
The goal of this clinical trial is to investigate neural constructs related to anxiety symptoms in response to Facing Your Fears (FYF) treatment in autistic participants with co-occurring anxiety. Researchers will compare participants receiving immediate FYF intervention to those in the waitlist control group (receiving treatment as usual) to see if there are differences in neural constructs and anxiety symptom changes over the study period. Participants will: - Complete the Facing Your Fears (FYF) intervention if assigned to the immediate treatment group - Continue their usual treatment during a waitlist period if assigned to the control group, followed by the opportunity to participate in FYF intervention after the waiting period ends - Complete assessments of neural constructs, anxiety symptoms, and other measures Type: Interventional Start Date: Apr 2025 |
Probiotic Administration for Adolescent Depression
University of California, San Francisco
Depression
This double-blind, placebo-controlled clinical trial will examine the effect of probiotic
Visbiome on the brain and gut microbiome of individuals 15 to 24 years of age. expand
This double-blind, placebo-controlled clinical trial will examine the effect of probiotic Visbiome on the brain and gut microbiome of individuals 15 to 24 years of age. Type: Interventional Start Date: May 2025 |
Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)
The University of Texas Health Science Center at San Antonio
Post Traumatic Stress Disorder PTSD
This study is being done to see if Prolonged Exposure (PE), a well-researched, very
effective individual (one-to-one) behavioral therapy designed to help people to directly
deal with traumatic events they have suffered in the past, can be combined with
intranasal esketamine (ketamine) for the treat1 expand
This study is being done to see if Prolonged Exposure (PE), a well-researched, very effective individual (one-to-one) behavioral therapy designed to help people to directly deal with traumatic events they have suffered in the past, can be combined with intranasal esketamine (ketamine) for the treatment of posttraumatic stress disorder (PTSD) to enhance treatment benefits. Ketamine nasal spray is a drug approved by the U.S. Food & Drug Administration (FDA) for treatment resistant depression. Combined with PE, intranasal ketamine may help to augment PE and further reduce participants' PTSD symptoms. Type: Interventional Start Date: Jun 2025 |
Long-term Potentiation Disruption Underlying Cognitive Impairment in ECT
University of New Mexico
Major Depressive Disorder
Bipolar Disorder II
Cognitive problems, like memory loss, are common after brain injuries like trauma or
stroke. These problems make daily life harder, and the investigators don't yet know the
best ways to help the brain recover. Scientists think that a process in the brain called
long-term potentiation (LTP) is impor1 expand
Cognitive problems, like memory loss, are common after brain injuries like trauma or stroke. These problems make daily life harder, and the investigators don't yet know the best ways to help the brain recover. Scientists think that a process in the brain called long-term potentiation (LTP) is important for memory and learning. When LTP isn't working properly, it may cause problems with thinking and memory. But studying LTP in people is hard because it happens deep inside the brain. Our research uses a treatment called electroconvulsive therapy (ECT) to better understand LTP. ECT is a treatment for severe depression that works by causing a controlled seizure in the brain. While ECT often helps depression, it can temporarily cause memory and thinking problems, which usually improve over time. This makes ECT a good way to study how thinking and memory recover. The investigators will use a tool called electroencephalography (EEG) to measure brain activity during different stages of ECT treatment. EEG is a safe and non-invasive way to track changes in LTP. Specifically, the investigators will measure how the brain responds to visual signals using something called visual evoked potentials (VEPs). These signals can show how LTP is affected by ECT. The study's main goal is to track changes in LTP using VEPs during and after ECT. By studying these changes, the investigators hope to learn how ECT affects the brain and how it recovers. This could help improve treatments for brain injuries and other conditions that cause memory and thinking problems. Type: Interventional Start Date: Jan 2025 |
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression
The University of Texas Health Science Center, Houston
Bipolar II Disorder
Depression, Bipolar
Suicidality
The purpose of the study is to assess the safety and acceptability of up to two
sequential administrations of 25 mg psilocybin with additional therapeutic support in
decreasing suicidality in patients with Bipolar Disorder (BD II) depression. expand
The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression. Type: Interventional Start Date: Mar 2025 |
The Nuestros Días ("Our Days") Study
University of Alabama at Birmingham
Caregiver Burden
Well-Being, Psychological
Stress, Psychological
Depression
Anxiety
The goal of this observational study is to understand how contextual, individual-level,
and cultural factors influence the daily and long-term well-being of caregivers of
relatives with memory problems or dementia. The study focuses on caregivers from the
Hispanic and Latino community. The main que1 expand
The goal of this observational study is to understand how contextual, individual-level, and cultural factors influence the daily and long-term well-being of caregivers of relatives with memory problems or dementia. The study focuses on caregivers from the Hispanic and Latino community. The main questions it aims to answer are: - What daily factors increase (i.e., risk factors) or decrease (i.e., protective factors) the daily odds of depression and anxiety symptoms reported by caregivers? - How do these symptoms vary over time? - Do variations in depression and anxiety symptoms predict distal health outcomes? Participants will: - Complete an online baseline survey to understand their caregiving situation. - Fill out daily surveys online for three weeks about their caregiving experiences and well-being. - Complete two follow-up surveys, along with daily surveys, six and twelve months after the baseline survey. All the study information and surveys can be completed in English or Spanish based on the participant's preference. Type: Observational Start Date: Mar 2023 |
Study of Lumateperone in the Treatment of Patients With Bipolar Mania
Intra-Cellular Therapies, Inc.
Bipolar Disorder, Manic
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute
treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic
episodes with mixed features (bipolar mania), with or without psychotic symptoms,
according to criteria of the Diagnostic1 expand
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5). Type: Interventional Start Date: Jul 2024 |
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (P1
VistaGen Therapeutics, Inc.
Social Anxiety Disorder
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and
tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray
(fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18
through 65 with Social Anxiety Disorder induce1 expand
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PALISADE-3 and choose to enter the distinct open-label extension phase of the study. Type: Interventional Start Date: Mar 2024 |
Psilocybin for Major Depressive Disorder (MDD)
Usona Institute
Depressive Disorder, Major
Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and
Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder
(MDD) will be enrolled. Participants will be randomly assigned to receive a single oral
dose of Psilocybin 25 mg, Psilocybin1 expand
Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, as assessed by the difference between groups in change in depressive symptoms from Baseline to Day 43 post-dose, and to characterize the durability of initial treatment effect and subsequent response to optional Psilocybin 25 mg re-administration(s) during the 1-year Follow-up Period. Type: Interventional Start Date: Mar 2024 |
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
Neumora Therapeutics, Inc.
Major Depressive Disorder
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the
effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants
with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up
to 35 days), and a 6-week Treatmen1 expand
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501). Type: Interventional Start Date: Dec 2023 |
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressiv1
Neumora Therapeutics, Inc.
Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the
effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants
with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up
to 28 days), and a 6-week Treat1 expand
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501). Type: Interventional Start Date: Dec 2023 |
Effect of Vagal Nerve Stimulation on Gastric Motor Functions
Mayo Clinic
Epilepsy
Depression
The specific aim of this study is to compare simultaneous assessment of gastric emptying
and gastric accommodation in response to the same caloric meal before and three months
after activation of left cervical VNS. Our hypothesis is that cervical VNS increases
gastric accommodation and accelerates1 expand
The specific aim of this study is to compare simultaneous assessment of gastric emptying and gastric accommodation in response to the same caloric meal before and three months after activation of left cervical VNS. Our hypothesis is that cervical VNS increases gastric accommodation and accelerates gastric emptying. Type: Interventional Start Date: Aug 2025 |
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Diso1
Intra-Cellular Therapies, Inc.
Major Depressive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group,
fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an
inadequate response to ongoing ADT. expand
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT. Type: Interventional Start Date: May 2023 |
Non-Inferiority Trial of TrIGR for PTSD
VA Office of Research and Development
PTSD
Trauma-related guilt is common and impairing among trauma survivors, particularly among
Veterans with posttraumatic stress disorder (PTSD). The investigators' work shows that a
brief treatment targeting trauma-related guilt, Trauma Informed Guilt Reduction Therapy
(TrIGR), can reduce guilt and PTSD1 expand
Trauma-related guilt is common and impairing among trauma survivors, particularly among Veterans with posttraumatic stress disorder (PTSD). The investigators' work shows that a brief treatment targeting trauma-related guilt, Trauma Informed Guilt Reduction Therapy (TrIGR), can reduce guilt and PTSD and depression symptoms. Whether TrIGR is no less effective than longer, more resource heavy PTSD treatments disseminated by by VA, like cognitive processing therapy (CPT), is the next critical question that this study will seek to answer. 158 Veterans across two VA sites will be randomized to TrIGR or CPT to evaluate changes in PTSD, depression, guilt and shame symptoms across the two treatments. Type: Interventional Start Date: Jun 2023 |
Cognitive and Affective Processes Online
University of Minnesota
Depression
This study will provide data for evaluating the psychometric characteristics of the tests
assessing cognitive flexibility, including their (1) internal consistency, (2)
feasibility and tolerability, their (3) convergent and discriminant validity of cognitive
and affective constructs such as those i1 expand
This study will provide data for evaluating the psychometric characteristics of the tests assessing cognitive flexibility, including their (1) internal consistency, (2) feasibility and tolerability, their (3) convergent and discriminant validity of cognitive and affective constructs such as those introduced to understand mental disorders, and (4) sensitivity (and correspondence) to individual differences. For these tests to be useful in studying clinical conditions, they must show adequate reliability, validity, and sensitivity in large samples of convenience. Type: Observational Start Date: Feb 2023 |
Mindful Self-Compassion for Anxiety Disorders and Depression
Georgetown University
Anxiety Disorders
Generalized Anxiety Disorder
Social Anxiety Disorder
Social Phobia
Panic Disorder
The study will compare 8-week Mindful Self-Compassion training, compared to a control
group that does not receive the intervention, on anxiety and depression symptom severity
in patients with diagnosed anxiety disorders (generalized anxiety disorder, social
anxiety disorder, and panic disorder) or1 expand
The study will compare 8-week Mindful Self-Compassion training, compared to a control group that does not receive the intervention, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder. Type: Interventional Start Date: Jan 2022 |
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psych1
Maastricht University Medical Center
Mood Disorders
Anxiety Disorders
Psychotic Disorders
A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and
multi-centre randomized clinical trial (RCT) to establish the benefits of
pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric
patients suffering from mood, anxiety, or psychotic disorder1 expand
A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders. Type: Interventional Start Date: Feb 2023 |
Reducing Psychological Barriers to PrEP Persistence Among Pregnant and Postpartum Women in Cape Tow1
Boston University Charles River Campus
Depression
Posttraumatic Stress Disorder
Pregnancy Related
Medication Adherence
Pregnant women in South Africa (SA) are at high risk of HIV acquisition. Pre-exposure
prophylaxis (PrEP) use during pregnancy is both safe and effective in preventing HIV.
However, posttraumatic stress (associated with intimate partner violence and/or other
traumas) and depression negatively impact1 expand
Pregnant women in South Africa (SA) are at high risk of HIV acquisition. Pre-exposure prophylaxis (PrEP) use during pregnancy is both safe and effective in preventing HIV. However, posttraumatic stress (associated with intimate partner violence and/or other traumas) and depression negatively impact PrEP adherence among women in SA. Addressing posttraumatic stress and depression will likely improve PrEP adherence and persistence (i.e., sustained PrEP adherence over time) during pregnancy and breastfeeding, which are periods of dramatically increased HIV risk. The overarching goal of this proposal is to develop and test the feasibility and acceptability of a cognitive behavioral intervention that targets common underlying factors of posttraumatic stress and depression to improve PrEP adherence and persistence during pregnancy and the postpartum transition. The specific aims of the project are to (1) explore the mechanisms by which posttraumatic stress and depression impact PrEP adherence and persistence during pregnancy via qualitative interviews; (2) develop a brief PrEP adherence and persistence intervention (~4 sessions) that reduces the negative impact of psychological mechanisms common to posttraumatic stress and depression on PrEP use, and builds behavioral skills to improve self-care; and (3) evaluate the feasibility, acceptability, and signals of preliminary efficacy of the intervention, which will be integrated into antenatal care, in a pilot randomized controlled trial. All data will be collected in the Midwife Obstetrics Unit (MOU) in Gugulethu, a peri-urban settlement and former township community outside of Cape Town, SA. Type: Interventional Start Date: Apr 2025 |
- Previous
- Next